Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the best multibagger penny stocks to invest in. On March 31, Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) and Citeline expanded their strategic partnership to further develop the artificial intelligence-enabled ClinTech Platform.
Photo by Pietro Jeng on Pexels
The expanded partnership also underscores the company’s commitment to building a more predictive and patient-centered biopharmaceutical ecosystem. It also follows the integration of Citeline’s SmartSolutions into the Recursion platform to provide data access during early development stages.
The expanded partnership paves the way for integrating Citeline’s real-world data and evidence capabilities into Recursion’s end-to-end platform. The integration will strengthen the platform’s foundation, enabling more precise trial design, improved site selection, and informed development decisions.
The addition of Citeline’s data and evidence capabilities to the company’s robust platform is also poised to support pipeline development. The ClinTech platform is already yielding results, including 30%-60% improvements in enrollment, affirming the importance of integration.
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is a clinical-stage “TechBio” company that uses artificial intelligence (AI), machine learning, automation, and high-throughput biology to enhance drug discovery and development.
While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: Motley Fool’s 10 High-Growth Stock Picks and 8 Best Blue Chip AI Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
